<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006004</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068012</org_study_id>
    <secondary_id>E-1599</secondary_id>
    <nct_id>NCT00006004</nct_id>
  </id_info>
  <brief_title>Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer</brief_title>
  <official_title>A Randomized Phase II Trial of Paclitaxel-Carboplatin or Gemicitabine-Cisplatin in ECOG Performance Status 2 Non-Small Cell Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells. It is not
      yet known which combination chemotherapy regimen is more effective for treating non-small
      cell lung cancer.

      PURPOSE: Randomized phase II trial to compare the effectiveness of two combination
      chemotherapy regimens in treating patients who have non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare overall survival, response rate, and time to progression of patients with
           non-small cell lung cancer treated with paclitaxel and carboplatin versus gemcitabine
           and cisplatin.

        -  Compare the toxicities of each of these 2 regimens in this patient population.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to weight
      loss in the past 6 months (less than 5% vs at least 5%) and disease stage (stage IIIB with
      pleural or pericardial effusion or pleural implants vs stage IV/recurrent). Patients are
      randomized to one of two treatment arms.

        -  Arm I: Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 15-30
           minutes on day 1.

        -  Arm II: Patients receive gemcitabine IV over 30 minutes on days 1 and 8 followed by
           cisplatin IV over 1 hour on day 1 only.

      Treatment continues in both arms every 21 days for up to 6 courses in the absence of
      unacceptable toxicity or disease progression.

      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
      annually thereafter.

      PROJECTED ACCRUAL: Approximately 40-90 patients (20-45 per arm) will be accrued for this
      study within 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed non-small cell lung carcinoma of any of the
             following subtypes:

               -  Squamous cell

               -  Adenocarcinoma

               -  Large cell anaplastic

               -  Bronchioalveolar

               -  Non-small cell carcinoma not otherwise specified

          -  No small cell anaplastic elements allowed

          -  Must have:

               -  Recurrent disease after prior radiotherapy or surgery OR

               -  Stage IV disease with distant metastases OR

               -  Stage IIIB disease presenting with pleural or pericardial effusion on CT or chest
                  x-ray or pleural implants documented pathologically or on CT or chest x-ray

          -  Bidimensionally measurable or evaluable disease

          -  Brain metastases allowed provided clinically stable after treatment with surgery
             and/or radiotherapy

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG 2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute neutrophil count at least 1,500/mm3

          -  Platelet count at least 100,000/mm3

        Hepatic:

          -  Bilirubin no greater than 1.5 mg/dL

          -  SGOT no greater than 5 times upper limit of normal

        Renal:

          -  Creatinine no greater than 1.5 mg/dL OR

          -  Creatinine clearance at least 60 mL/min

        Cardiovascular:

          -  No uncontrolled high blood pressure, unstable angina, or congestive heart failure

          -  No myocardial infarction within the past 6 months

          -  No serious ventricular arrhythmias requiring medication

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No other active malignancies requiring ongoing treatment

          -  No uncontrolled serious active infections

          -  No suspected hypersensitivity to agents that utilize Cremophor

          -  No evidence of neuropathy grade 2 or greater by history or physical examination

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy for non-small cell lung cancer

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

          -  No prior radiotherapy to only site of measurable or evaluable disease unless
             subsequent progression documented by physical exam, radiograph, or pathology

          -  Recovered from prior radiotherapy

          -  No concurrent radiotherapy except for whole brain radiation for developing brain
             metastases

        Surgery:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corey J. Langer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Hospital - Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Methodist Medical Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Lutheran Hospital</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50316-2301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alegent Health-Midlands Community Hospital</name>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <zip>68128-4157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Northern New Jersey</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - University of New Mexico HSC</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Oklahoma</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Scott and White Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - St. Vincent Hospital Cancer Center, Green Bay</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54307-3453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Enfermedades Neoplasicas</name>
      <address>
        <city>Lima</city>
        <zip>34</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan City Hospital</name>
      <address>
        <city>San Juan</city>
        <zip>00936-7344</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Peru</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Langer C, Li S, Schiller J, Tester W, Rapoport BL, Johnson DH; Eastern Cooperative Oncology Group. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol. 2007 Feb 1;25(4):418-23.</citation>
    <PMID>17264337</PMID>
  </results_reference>
  <results_reference>
    <citation>Tester WJ, Stephenson P, Langer CJ, et al.: ECOG 1599: randomized phase II study of paclitaxel/carboplatin or gemcitabine/cisplatin in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC). [Abstract] J Clin Oncol 22 (Suppl 14): A-7055, 630s, 2004.</citation>
  </results_reference>
  <results_reference>
    <citation>Langer CJ, Stephenson P, Schiller J, et al.: ECOG 1599: randomized phase II study of paclitaxel/carboplatin vs cisplatin/gemcitabine in performance status (PS) 2 patients with treatment-naive advanced NSCLC. [Abstract] Lung Cancer 41 (Suppl 2): A-O52, S18, 2003.</citation>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 16, 2013</last_update_submitted>
  <last_update_submitted_qc>August 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2013</last_update_posted>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>squamous cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>adenosquamous cell lung cancer</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

